Boston Scientific (NYSE: BSX) director adds 1,182 shares in August stock purchases
Rhea-AI Filing Summary
Boston Scientific Corp director David C. Habiger reported open-market purchases of Common Stock on two days in August 2026. He bought 1,042 shares on August 3 at a weighted average price of $48.0655 per share and 140 shares on August 4 at a weighted average price of $48.5879 per share. Each trade was executed through multiple transactions within stated price ranges, with detailed per-trade pricing available on request.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 1,182 shares
Net Buy
2 txns
Insider
Habiger David C
Role
Director
Bought
1,182 shs ($57K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock F2 | 140 | $48.5879 | $7K |
| Purchase | Common Stock F1 | 1,042 | $48.0655 | $50K |
Holdings After Transaction:
Common Stock — 15,060 shares (Direct)
Footnotes (2)
- F1. Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $48.055 to $48.070, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- F2. Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $48.54 to $48.60, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Key Figures
Shares purchased 2026-08-03: 1,042 shares
Shares purchased 2026-08-04: 140 shares
Net shares purchased: 1,182 shares
+2 more
5 metrics
Shares purchased 2026-08-03
1,042 shares
Common Stock bought in open-market transactions at weighted average $48.0655 per share
Shares purchased 2026-08-04
140 shares
Common Stock bought in open-market transactions at weighted average $48.5879 per share
Net shares purchased
1,182 shares
Total Boston Scientific Common Stock purchased across both reported transactions
Price range 2026-08-03
$48.055 to $48.070 per share
Range of prices for the 1,042-share purchase; weighted average $48.0655
Price range 2026-08-04
$48.54 to $48.60 per share
Range of prices for the 140-share purchase; weighted average $48.5879
Key Terms
weighted average purchase price, multiple transactions, open market or private transaction
3 terms
weighted average purchase price financial
"Represents the weighted average purchase price for the shares purchased"
The weighted average purchase price is the average cost per share you paid across multiple buys, calculated so larger purchases count more than smaller ones. Imagine buying apples at different prices: the overall price you effectively paid depends on how many apples you bought at each price. Investors use it to measure true cost basis, calculate gains or losses, decide when to sell, and manage taxes and portfolio performance.
multiple transactions financial
"These shares were purchased in multiple transactions at prices ranging"
open market or private transaction financial
"Transaction code P described as Purchase in open market or private transaction"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were the price ranges for the BSX purchases reported by David C. Habiger?
For the 1,042-share purchase on August 3, 2026, trades occurred between $48.055 and $48.070 per share. For the 140-share purchase on August 4, 2026, trades occurred between $48.54 and $48.60 per share.
Were the BSX insider purchases made in open-market transactions?
Yes. Both transactions are coded "P" with the description "Purchase in open market or private transaction", indicating the shares were acquired through market or similar purchase activity, rather than option exercises or gifts.
Does the BSX Form 4 indicate a Rule 10b5-1 trading plan?
No. The Form 4 indicates the Rule 10b5-1 checkbox is not affirmed (set to false), and the footnotes describe only weighted average pricing and multiple executions, without referencing any trading plan.